{"entity":{"id":"bria-imt","kind":"drug","name":"Bria-IMT","aka":[],"tldr":"Bria-IMT is an off-the-shelf immunotherapy made from laboratory-grown cancer cells, from BriaCell Therapeutics. It is being tested with a checkpoint inhibitor in a phase 3 trial in metastatic breast cancer.","summary":"Bria-IMT is the lead candidate of BriaCell Therapeutics, which describes it as a patented, off-the-shelf, cell-based targeted immunotherapy. It is being compared, with the checkpoint inhibitor retifanlimab, against treatment of the physician's choice in advanced metastatic breast cancer in the phase 3 trial NCT06072612 (BRIA-ABC), which plans 404 participants. BriaCell states that the FDA granted Bria-IMT Fast Track status.","status":"phase-3","asOf":"2026-11-04","links":[{"label":"BriaCell Therapeutics","url":"https://briacell.com/"},{"label":"ClinicalTrials.gov: NCT06072612","url":"https://clinicaltrials.gov/study/NCT06072612"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":["briacell"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06072612"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"modality":"Off-the-shelf cell-based immunotherapy","mechanism":"Described by BriaCell Therapeutics as a patented, off-the-shelf, cell-based targeted immunotherapy, given with an immune checkpoint inhibitor. The ClinicalTrials.gov record of the phase 3 trial lists SV-BR-1-GM, cyclophosphamide and interferon infiltration of the inoculation site among the interventions of the Bria-IMT regimen.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bria-imt/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"company":[{"id":"briacell","kind":"company","name":"BriaCell Therapeutics","route":"/companies/briacell/"}],"trial":[{"id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/"}]}}